Biotechnology Company Demetrix Works Toward Cannabinoid Biosynthesis Commercialization Following $50M Series A

Exclusive Interview with Demetrix CEO Jeff Ubersax, PhD Biotechnology companies are hard at work finding ways to commercialize biosynthetic cannabinoids, and among those companies is Demetrix. CEO Jeff Ubersax told New Cannabis Ventures how he sees his company’s combination of funding, team experience and solid IP will help it carve out a space in the
[Read More ...]

Originally posted on Biotechnology Company Demetrix Works Toward Cannabinoid Biosynthesis Commercialization Following $50M Series A via Vic Neufeld Medical Marijuana News